Cytokeratin-19 fragments,nucleosomes and neuron-specific enolase as early measures of chemotherapy response in non-small cell lung cancer

Abstract

Aim

To investigate the reduction in the serum level of cytokeratin-19 fragments (CYFRA 21–1), nucleosomes and neuron-specific enolase (NSE) as early measures of the response to chemotherapy in non-small cell lung cancer (NSCLC).

Methods

Forty-two consecutive patients with locally advanced NSCLC were included. All patients received platinum-based chemotherapy. Staging investigations and quantification of CYFRA 21–1, nucleosomes and NSE (using enzyme-linked immunosorbent assay, ELISA) were performed before the start of treatment and after the second cycle of chemotherapy. According to the response to chemotherapy, patients were classified into 3 groups: (I) disease regression, (II) stable disease, and (III) progressive disease. The reduction in the levels of tumor markers was correlated with the response to chemotherapy.

Results

After the second cycle of chemotherapy, groups I and II had significantly decreased serum levels of CYFRA 21–1 (p<0.05). Similarly, the concentration of nucleosomes was significantly lower than the baseline levels in groups I (p=0.0008) and II (p=0.003). The reduction of both CYFRA 21–1 and nucleosome levels was not significant for patients in group III. In all groups the reduction of NSE levels in response to chemotherapy was not significant. As a marker of response to chemotherapy, CYFRA 21–1 showed the highest sensitivity (88.9%) and specificity (77.4%) compared with nucleosomes (77.8% and 58.1% respectively) and NSE (66.7% and 51.8% respectively).

Conclusion

The reduction in the serum level of CYFRA 21–1 and nucleosomes may be used for early identification of NSCLC patients with good response to chemotherapy.

Keywords

Lung cancer Non-small cell Tumor markers Response Chemotherapy

References

Kumar

, Guleria

, Singh

, Bharti

A.C.

, Mohan

, Das

B.C.

. Plasma nucleosome levels might predict response to therapy in patients with advanced non-small-cell lung cancer. Clin Lung Cancer 2010; 11: 36–44.

Boring

C.C.

, Squires

T.S.

, Tong

, Montgomery

. Cancer statistics, 1994. CA Cancer J Clin 1994; 44: 7–26.

Pfister

D.G.

, Johnson

D.H.

, Azzoli

C.G.

. American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: update 2003. J Clin Oncol 2004; 22: 330–53.

Socinski

M.A.

, Schell

M.J.

, Peterman

. Phase III trial comparing a defined duration of therapy versus continuous therapy followed by second-line therapy in advanced-stage IIIB/IV non-small-cell lung cancer. J Clin Oncol 2002; 20: 1335–43.

Nisman

, Biran

, Heching

. Prognostic role of serum cytokeratin 19 fragments in advanced non-small-cell lung cancer: association of marker changes after two chemotherapy cycles with different measures of clinical response and survival. Br J Cancer 2008; 98: 77–9.

Ardizzoni

, Cafferata

M.A.

, Tiseo

. Decline in serum carcinoembryonic antigen and cytokeratin 19 fragment during chemotherapy predicts objective response and survival in patients with advanced nonsmall cell lung cancer. Cancer 2006; 107: 2842–9.

Buccheri

, Torchio

, Ferrigno

. Clinical equivalence of two cytokeratin markers in non-small cell lung cancer: a study of tissue polypeptide antigen and cytokeratin 19 fragments. Chest 2003; 124: 622–32.

Vollmer

R.T.

, Govindan

, Graziano

S.L.

. Serum CYFRA 21–1 in advanced stage non-small cell lung cancer: an early measure of response. Clin Cancer Res 2003; 9: 1728–33.

Barlesi

, Gimenez

, Torre

J.P.

. Prognostic value of combination of Cyfra 21–1, CEA and NSE in patients with advanced non-small cell lung cancer. Respir Med 2004; 98: 357–62.

10.

Muley

, Dienemann

, Ebert

. CYFRA 21–1 and CEA are independent prognostic factors in 153 operated stage I NSCLC patients. Anticancer Res 2004; 24: 1953–6.

11.

Pujol

J.L.

, Molinier

, Ebert

. CYFRA 21–1 is a prognostic determinant in non-small-cell lung cancer: results of a meta-analysis in 2063 patients. Br J Cancer 2004; 90: 2097–105.

12.

Kornberg

R.D.

, Lorch

. Twenty-five years of the nucleosome, fundamental particle of the eukaryote chromosome. Cell 1999; 98: 285–94.

13.

Luger

, Mader

A.W.

, Richmond

R.K.

, Sargent

D.F.

, Richmond

T.J.

. Crystal structure of the nucleosome core particle at 2.8 A resolution. Nature 1997; 389: 251–60.

14.

Holdenrieder

, Stieber

, von Pawel

. Circulating nucleosomes predict the response to chemotherapy in patients with advanced non-small cell lung cancer. Clin Cancer Res 2004; 10: 5981–7.

15.

Kerr

J.F.

, Winterford

C.M.

, Harmon

B.V.

. Apoptosis. Its significance in cancer and cancer therapy. Cancer 1994; 73: 2013–26.

16.

Lichtenstein

A.V.

, Melkonyan

H.S.

, Tomei

L.D.

, Umansky

S.R.

. Circulating nucleic acids and apoptosis. Ann N Y Acad Sci 2001; 945: 239–49.

17.

Stroun

, Maurice

, Vasioukhin

. The origin and mechanism of circulating DNA. Ann N Y Acad Sci 2000; 906: 161–8.

18.

Sienkiewicz-Jarosz

, Galecka-Wolska

, Bidzinski

. Predictive value of selected biochemical markers of brain damage for functional outcome in ischaemic stroke patients. Neurol Neurochir Pol 2009; 43: 126–33.

19.

Holdenrieder

, von Pawel

, Dankelmann

. Nucleosomes, ProGRP, NSE, CYFRA 21–1, and CEA in monitoring first-line chemotherapy of small cell lung cancer. Clin Cancer Res 2008; 14: 7813–21.

20.

Molina

, Filella

, Auge

J.M.

. ProGRP: a new biomarker for small cell lung cancer. Clin Biochem 2004; 37: 505–11.

21.

Schneider

, Philipp

, Velcovsky

H.G.

, Morr

, Katz

. Pro-gastrin-releasing peptide (ProGRP), neuron specific enolase (NSE), carcinoembryonic antigen (CEA) and cytokeratin 19-fragments (CYFRA 21–1) in patients with lung cancer in comparison to other lung diseases. Anticancer Res 2003; 23: 885–93.

22.

Amoura

, Koutouzov

, Chabre

. Presence of anti-nucleosome autoantibodies in a restricted set of connective tissue diseases: antinucleosome antibodies of the IgG3 subclass are markers of renal pathogenicity in systemic lupus erythematosus. Arthritis Rheum 2000; 43: 76–84.

23.

Bonner

J.A.

, Sloan

J.A.

, Rowland

K.M.

Jr . Significance of neuron-specific enolase levels before and during therapy for small cell lung cancer. Clin Cancer Res 2000; 6: 597–601.

24.

Miller

A.B.

, Hoogstraten

, Staquet

, Winkler

. Reporting results of cancer treatment. Cancer 1981; 47: 207–14.

25.

Tyczynski

J.E.

, Bray

, Parkin

D.M.

. Lung cancer in Europe in 2000: epidemiology, prevention, and early detection. Lancet Oncol 2003; 4: 45–55.

26.

Werner-Wasik

, Xiao

, Pequignot

, Curran

W.J.

, Hauck

. Assessment of lung cancer response after nonoperative therapy: tumor diameter, bidimensional product, and volume. A serial CT scan-based study. Int J Radiat Oncol Biol Phys 2001; 51: 56–61.

27.

Lai

R.S.

, Chen

C.C.

, Lee

P.C.

, Lu

J.Y.

. Evaluation of cytokeratin 19 fragment (CYFRA 21–1) as a tumor marker in malignant pleural effusion. Jpn J Clin Oncol 1999; 29: 421–4.

28.

Pujol

J.L.

, Grenier

, Daures

J.P.

, Daver

, Pujol

, Michel

F.B.

. Serum fragment of cytokeratin subunit 19 measured by CYFRA 21–1 immunoradiometric assay as a marker of lung cancer. Cancer Res 1993; 53: 61–6.

29.

Nisman

, Lafair

, Heching

. Evaluation of tissue polypeptide specific antigen, CYFRA 21–1, and carcinoembryonic antigen in nonsmall cell lung carcinoma: does the combined use of cytokeratin markers give any additional information?. Cancer 1998; 82: 1850–9.

30.

Reinmuth

, Brandt

, Semik

. Prognostic impact of Cyfra21–1 and other serum markers in completely resected non-small cell lung cancer. Lung Cancer 2002; 36: 265–70.

31.

Foa

, Fornier

, Miceli

. Tumour markers CEA, NSE, SCC, TPA and CYFRA 21.1 in resectable non-small cell lung cancer. Anticancer Res 1999; 19: 3613–8.

32.

Niklinski

, Furman

, Burzykowski

. Preoperative CYFRA 21–1 level as a prognostic indicator in resected primary squamous cell lung cancer. Br J Cancer 1996; 74: 956–60.

33.

Schneider

, Philipp

, Salewski

, Velcovsky

H.G.

. Pro-gastrin-releasing peptide (ProGRP) and neuron specific enolase (NSE) in therapy control of patients with small-cell lung cancer. Clin Lab 2003; 49: 35–42.

34.

Pottgen

, Levegrun

, Theegarten

. Value of 18F-fluoro-2-deoxy-D-glucose-positron emission tomography/computed tomography in non-small-cell lung cancer for prediction of pathologic response and times to relapse after neoadjuvant chemoradiotherapy. Clin Cancer Res 2006; 12: 97–106.

35.

Holdenrieder

, Stieber

, von Pawel

. Early and specific prediction of the therapeutic efficacy in non-small cell lung cancer patients by nucleosomal DNA and cytokeratin-19 fragments. Ann N Y Acad Sci 2006; 1075: 244–57.

36.

Kulpa

, Wojcik

, Reinfuss

, Kolodziejski

. Carcinoembryonic antigen, squamous cell carcinoma antigen, CYFRA 21–1, and neuron-specific enolase in squamous cell lung cancer patients. Clin Chem 2002; 48: 1931–7.

37.

Suzuki

, Ishikawa

, Satoh

. Preoperative CYFRA 21–1 levels as a prognostic factor in c-stage I non-small cell lung cancer. Eur J Cardiothorac Surg 2007; 32: 648–52.